Cargando…

Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer

Colorectal cancer (CRC) is the most common gastrointestinal type of cancer. The overexpression of Ras proteins, particularly p21Ras, are involved in the development of CRC. However, the subtypes of the p21Ras proteins that are overexpressed and the mutation status remain unknown restricting the deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Shuang, Feng, Qiang, Pan, Xin-Yan, Zou, Hong, Chen, Hao-Bin, Wang, Peng, Zhou, Xin-Liang, Hong, Yan-Ling, Song, Shu-Ling, Yang, Ju-Lun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360420/ https://www.ncbi.nlm.nih.gov/pubmed/28259994 http://dx.doi.org/10.3892/ijmm.2017.2903

Ejemplares similares

Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells
por: Liu, Fang-Rui, et al.
Publicado: (2018)

Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression
por: Wang, Mingjuan, et al.
Publicado: (2018)

Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer
por: Dai, Fang, et al.
Publicado: (2021)

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480
por: Huang, Chen-Chen, et al.
Publicado: (2021)

Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480
por: Huang, Chen-Chen, et al.
Publicado: (2021)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

UBN2 promotes tumor progression via the Ras/MAPK pathway and predicts poor prognosis in colorectal cancer
por: Zhao, Ya-li, et al.
Publicado: (2019)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

Adaptor SKAP-55 Binds p21(ras) Activating Exchange Factor RasGRP1 and Negatively Regulates the p21(ras)-ERK Pathway in T-Cells
por: Schneider, Helga, et al.
Publicado: (2008)

TOB1 suppresses proliferation in K‐Ras wild‐type pancreatic cancer
por: Bai, Yuru, et al.
Publicado: (2019)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

Brain Organization of Apolygus lucorum: A Hemipteran Species With Prominent Antennal Lobes
por: Xie, Gui-Ying, et al.
Publicado: (2019)

Ras hyperactivation versus overexpression: Lessons from Ras dynamics in Candida albicans
por: Pratyusha, Vavilala A., et al.
Publicado: (2018)

Hypomethylation Causes MIR21 Overexpression in Tumors
por: Lu, Jun, et al.
Publicado: (2020)

CARD9 mediates Dectin-1–induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity
por: Jia, Xin-Ming, et al.
Publicado: (2014)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Zheng, Bobo, et al.
Publicado: (2019)

Impaired balance between coagulation and fibrinolysis plays a prominent role in patients with sepsis
por: Umemura, Y, et al.
Publicado: (2014)

The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes
por: Huo, Qingji, et al.
Publicado: (2023)

Immunohistochemical detection of the ras oncogene p21 product in an experimental tumour and in human colorectal neoplasms.
por: Williams, A. R., et al.
Publicado: (1985)

Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2017)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

AKT Axis, miR-21, and RECK Play Pivotal Roles in Dihydroartemisinin Killing Malignant Glioma Cells
por: Shao, Ying-Ying, et al.
Publicado: (2017)

Author Correction: Ras hyperactivation versus overexpression: Lessons from Ras dynamics in Candida albicans
por: Pratyusha, Vavilala A., et al.
Publicado: (2019)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
por: Cai, Changjing, et al.
Publicado: (2022)

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
por: Valladares-Ayerbes, Manuel, et al.
Publicado: (2022)

A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues
por: Yang, Ju-Lun, et al.
Publicado: (2016)

Solar prominences
por: Vial, Jean-Claude, et al.
Publicado: (2015)

Prominent visitors
por: CERN PhotoLab
Publicado: (1975)

Solar prominences
por: Tandberg-Hanssen, Einar
Publicado: (1974)

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vl8gqllsvqgu1a3ij5uu44t8rr